BMC Cancer | |
Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer | |
Research Article | |
Rohini Sharma1  Janet Graham2  Hani Gabra3  Sarah Blagden3  | |
[1] Department of Experimental Medicine, Imperial College, London, UK;Department of Oncology, University of Glasgow, Glasgow, UK;Ovarian Cancer Action (HHMT) Research Centre, Imperial College, London, UK; | |
关键词: ovarian cancer; resistance; chemotherapy; dose-dense; carboplatin; paclitaxel; thrombocytopaenia; | |
DOI : 10.1186/1471-2407-11-289 | |
received in 2011-02-09, accepted in 2011-07-11, 发布年份 2011 | |
来源: Springer | |
【 摘 要 】
BackgroundPlatinum agents have shown demonstrable activity in the treatment of patients with platinum resistant, recurrent ovarian cancer when delivered in a "dose-dense" fashion. However, the development of thrombocytopenia limits the weekly administration of carboplatin to no greater than AUC 2. Paclitaxel has a well-described platelet sparing effect however its use to explicitly provide thromboprotection in the context of dose dense carboplatin has not been explored.MethodsWe treated seven patients with platinum resistant ovarian cancer who had previously received paclitaxel or who had developed significant peripheral neuropathy precluding the use of further full dose weekly paclitaxel.ResultsWe were able to deliver carboplatin AUC 3 and paclitaxel 20 mg/m2 with no thrombocytopenia or worsening of neuropathic side-effects, and with good activity.ConclusionsWe conclude that this regimen may be feasible and active, and could be formally developed as a "platinum-focussed dose-dense scaffold" into which targeted therapies that reverse platinum resistance can be incorporated, and merits further evaluation.
【 授权许可】
CC BY
© Sharma et al; licensee BioMed Central Ltd. 2011
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202311095075325ZK.pdf | 388KB | download |
【 参考文献 】
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]
- [15]
- [16]
- [17]
- [18]
- [19]
- [20]
- [21]
- [22]
- [23]
- [24]
- [25]
- [26]
- [27]
- [28]
- [29]